Currently, there are 103.54M common shares owned by the public and among those 97.48M shares have been available to trade.
The company’s stock has a 5-day price change of 16.23% and -21.25% over the past three months. NTLA shares are trading -17.07% year to date (YTD), with the 12-month market performance down to -63.05% lower. It has a 12-month low price of $5.90 and touched a high of $28.18 over the same period. NTLA has an average intraday trading volume of 3.54 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.78%, 18.87%, and -30.39% respectively.
Institutional ownership of Intellia Therapeutics Inc (NASDAQ: NTLA) shares accounts for 91.94% of the company’s 103.54M shares outstanding.
It has a market capitalization of $1.00B and a beta (3y monthly) value of 2.22. The earnings-per-share (ttm) stands at -$5.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.94% over the week and 7.81% over the month.
Analysts forecast that Intellia Therapeutics Inc (NTLA) will achieve an EPS of -1.03 for the current quarter, -1.0 for the next quarter and -3.97 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.3 while analysts give the company a high EPS estimate of -1.3. Comparatively, EPS for the current quarter was -1.52 a year ago. Earnings per share for the fiscal year are expected to increase by 19.90%, and 7.19% over the next financial year. EPS should grow at an annualized rate of 27.98% over the next five years, compared to -20.04% over the past 5-year period.
Looking at the support for the NTLA, a number of firms have released research notes about the stock. Wolfe Research stated their Outperform rating for the stock in a research note on April 21, 2025, with the firm’s price target at $21. H.C. Wainwright coverage for the Intellia Therapeutics Inc (NTLA) stock in a research note released on March 05, 2025 offered a Buy rating with a price target of $30. JP Morgan was of a view on February 28, 2025 that the stock is Neutral, while Goldman gave the stock Sell rating on February 28, 2025, issuing a price target of $9. Morgan Stanley on their part issued Equal-Weight rating on January 27, 2025.
